BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, said Executive Chairman Krishna Ella
The Hyderabad-based biotech company clarified late at night that in the "rush" to develop vaccines and file the necessary patents, BBIL had forgotten to include ICMR's name in the original filings.
Bharat Biotech's Rotovac vaccine, part of India's immunisation drive, linked to higher infant intussusception risk in a study published in the International Journal of Risk and Safety in Medicine.
Out of 926 participants of the study, around 50 percent complained of infections during the follow-up period, which was dominated by viral upper respiratory tract infections, the research showed.
Trials to evaluate the safety and immunogenicity of Mtbvac have started with a pivotal safety, immunogenicity and efficacy trial which has been planned to start in 2025, the release said.
The TYPBAR vaccine was first in India to get a World Health Organisation Good Manufacturing Practice (WHO-GMP) prequalification certificate
Slow public procurement of COVID-19 vaccines has meant that the only way those eligible can avail the booster is by paying at private hospitals, leading to very low demand for precautionary doses despite rising cases.
In the 60-minute documentary titled ‘The Vial – India’s Vaccine Story’, PM Modi said the need of the hour was to develop a vaccine and for that, decision-making “could not move at the speed of files”
Talking about the tough decision of imposing a nationwide lockdown to curb the spread of the virus, PM Modi, in History TV18's documentary ‘The Vial – India’s Vaccine Story’, said he was able to educate people that ‘Jaan hai toh jahaan hai’
History TV18’s 60-minute documentary, titled The Vial – India’s Vaccine Story, is the first to feature PM Narendra Modi where he speaks in detail about India’s victory over the Covid-19 pandemic
Marrying technology with a spirit to eliminate the virus from the country also led to ingenious solutions such as the use of drones to deliver vaccines
‘The Vial – India’s Vaccine Story’ revealed how residents of Malana, a village in Parvati Valley, claim they are the descendants of Alexander the Great and view outsiders --- including health workers --- with suspicion
Narrated by actor Manoj Bajpayee, the 60-minute documentary that aired at 8pm on Friday traces India’s journey from deciding to develop a vaccine on its own to becoming the world’s saviour by providing the jabs to several countries
He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.
In the past few months, there have been repeated instances of foreign drug regulators raising the red flag against medicines manufactured by Indian pharmaceutical firms
His comments came on Sunday in the backdrop of questions being raised about the quality of Indian drugs over the past few months.
The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose.
"Research linked incentive for Indian companies is very important. I would request the ministry to give tax breaks to any product that is created from patent filed in India. It will inspire entrepreneurs to go for innovation," he said.
Due to lack of rise in demand for booster doses, small private hospitals have showed no interest in procuring the vaccine despite the ease of administration it promises, say industry sources
The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc and Moderna Inc, meeting its main goals, Ocugen said.
Covaxin was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the US with no vaccine-related serious adverse events, Bharat Biotech’s partner in the country has announced
According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin.
The COVID-19 vaccine will now be offered to the adults earlier fully vaccinated with Covaxin or Covishield after the government incorporated changes in the CoWin app.
The nasal vaccine -- BBV154 -- received approval of the Drugs Controller General of India in November for restricted use in an emergency situation for those above 18 as a heterologous booster dose.
The Hyderabad-based Covaxin maker’s nasal vaccine will be introduced on Co-WIN by next week, sources said, adding that the pricing is yet to be decided